Eisai Drops Perampanel In Parkinson's, Plans Neuropathy Submission In 2010
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Development focus shifts after second failed Phase III trial in Parkinson’s disease. New studies in neuropathic pain and epilepsy employ doses up to 12 mg, compared to 2 mg and 4 mg doses in Parkinson’s studies